

Gender: Female | Birth year: 1980 | WHO: 2

Tumor: Lung - Small cell carcinoma | Lesions: Bone, Lung | Stage: IV

Summary

Clinical summary

Relevant systemic treatment history	3/2024-9/2024	Cisplatin+Etoposide
Relevant other oncological history	None	
Previous primary tumor	None	
Relevant non-oncological history	1/2019	Cerebrovascular accident

Recent molecular results

Small NGS Lung Panel (15-Sep-2024)

Biopsy location	Lung
Molecular tissue of origin prediction	Unknown
Tumor mutational load / burden	Unknown / TMB low (8)
Microsatellite (in)stability	Stable
HR status	Proficient
High driver mutations	TP53 R273H, SMARCA4 T910M
Amplified genes	None
Deleted genes	None
Homozygously disrupted genes	None
Gene fusions	None
Virus detection	None
Potentially actionable events with medium/low driver:	None

IHC resultsPD-L1: Score < 1%

Example trials that are open and potentially eligible (0)

None

Example trials that are open and potentially eligible but currently have no slots available (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose escalation - monotherapy		None

Example trials that are open but for which additional genes need to be tested to evaluate eligibility (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 05 PICKME3CA	Dose expansion - monotherapy - Other cancer types		Gene(s) PIK3CA not tested

Open cohorts with no slots available are shown in grey.

Trial Matching Summary

Example trials and cohorts that are potentially eligible, but are closed (1)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose expansion - monotherapy		None

Example trials and cohorts that are considered ineligible (5)

Trial	Cohort	Molecular	Ineligibility reasons
METC 02 KAYRAS	Applies to all cohorts below	None	G12D not detected in KRAS
	Dose expansion - monotherapy - Colorectum		No colorectal cancer
	Dose expansion - monotherapy - NSCLC		No lung non-small cell carcinoma
METC 03 NO-SEE797ES	Dose escalation - monotherapy		No variants in codon(s) C797 in EGFR
METC 04 TEDR1	Lung cancer C797S cohort		C797S not detected in EGFR
METC 05 PICKME3CA	Dose expansion - monotherapy - NSCLC		No lung non-small cell carcinoma

Open cohorts with no slots available are shown in grey.

Example trials and cohorts that are not evaluable or ignored (0)

None

Trial Matching Details

Potentially eligible open trials & cohorts

METC 01

Potentially eligible	Yes
Acronym	IEMOEN
Title	Phase I first-in-human study to evaluate safety of IEMOEN, a new PD-L1 inhibitor in advanced solid tumors

Rule	Reference	Evaluation
E-02	Has hemoglobin below 6 mmol/l	WARN Hemoglobin 8.2 mmol/L exceeds minimum of 6.0 mmol/L, but measurement occurred before 03-Aug-2024
E-03	Has absolute neutrophil count below 1.5 x 10^9/l	UNDETERMINED No measurement found for absolute neutrophil count
I-01	Patients must be ≥18 years old.	PASS Patient is at least 18 years old
I-02	IEMOEN monotherapy is indicated for the treatment of adults with advanced/metastatic solid tumors.	PASS Patient has solid primary tumor Tumor stage IV is considered metastatic
I-03	Patient should have exhausted applicable available standard-of-care treatments.	PASS Assumed exhaustion of SOC since patient has had prior cancer treatment
E-01	Has an active autoimmune disease that requires systemic treatment and poses a risk according to the investigator.	PASS Patient has no other condition belonging to category autoimmune disease

METC 01 - Dose escalation - monotherapy

Cohort ID	A
Potentially eligible?	Yes
Open for inclusion?	Yes
Has slots available?	No

METC 01 - Dose expansion - monotherapy

Cohort ID	B
Potentially eligible?	Yes
Open for inclusion?	No
Has slots available?	No

METC 05

Potentially eligible	Yes
Acronym	PICKME3CA
Title	A phase 1/2 trial of ABC123 +/- platinum doublet in PIK3CA-mutated solid cancer

Rule	Reference	Evaluation
I-03	ALAT and ASAT should be at most 3*ULN, or at most 5*ULN in case of liver metastases.	UNDETERMINED ASAT and ALAT are not present or cannot be evaluated
I-04	Patient has confirmed activating PIK3CA mutation	UNDETERMINED Gene(s) PIK3CA not tested in molecular data
I-01	Patient is ≥18 years old.	PASS Patient is at least 18 years old
I-02	Has locally advanced or metastatic cancer.	PASS Tumor stage IV is considered metastatic
I-05	Patient can not have a severe cardiac condition.	PASS Patient has no other condition belonging to category coronary artery disease Patient has no other condition belonging to category heart disease

METC 05 - Dose expansion - monotherapy - NSCLC

Cohort ID	A
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes

Rule	Reference	Evaluation
I-03	Has non small cell lung cancer.	FAIL Patient has no lung non-small cell carcinoma

METC 05 - Dose expansion - monotherapy - Other cancer types

Cohort ID	B
Potentially eligible?	Yes
Open for inclusion?	Yes
Has slots available?	Yes

Rule	Reference	Evaluation
I-03	Has solid cancer, other than non small cell lung cancer.	PASS Patient has no lung non-small cell carcinoma Patient has solid primary tumor

Other trials & cohorts

METC 02

Potentially eligible	No
Acronym	KAYRAS
Title	A phase 1/2 trial for first in-human usage of KAYRAS, a new specific KRAS G12D inhibitor in NSCLC and colorectal cancer

Rule	Reference	Evaluation
I-04	Patient has confirmed KRAS G12D mutation	FAIL None of G12D detected in gene KRAS

METC 02 - Dose expansion - monotherapy - NSCLC

Cohort ID	A
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes

Rule	Reference	Evaluation
I-02	KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer.	FAIL Patient has no lung non-small cell carcinoma

METC 02 - Dose expansion - monotherapy - Colorectum

Cohort ID	B
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes

Rule	Reference	Evaluation
I-02	KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer.	FAIL Patient has no colorectal cancer

METC 03

Potentially eligible	No
Acronym	NO-SEE797ES
Title	Phase I trial for development of NO-SEE797ES, a specific inhibitor for EGFR with C797 mutations but not C797S in solid tumors

Rule	Reference	Evaluation
I-03	Tumors should contain EGFR C797 but not EGFR C797S mutation.	FAIL No variants in codon(s) C797 detected in gene EGFR

METC 03 - Dose escalation - monotherapy

Cohort ID	A
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes

METC 04

Potentially eligible	No
Acronym	TEDR1
Title	TEDR1 Trial: A phase II trial to evaluate efficacy of specific EGFR inhibitors in lung cancer

Rule	Reference	Evaluation
I-3	Patient has a confirmed EGFR C797S mutation	FAIL
		None of C797S detected in gene EGFR

METC 04 - Lung cancer C797S cohort

Cohort ID	A
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes